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Previous experimental studies have shown pulmonary
vascular resistance to be significantly elevated5,6 and
lung water content to be increased5 with nonpulsatile
pulmonary flow. Few reports, however, confirm sequel-
ae caused by nonpulsatile pulmonary flow in the clini-
cal setting, that is, in patients after BCPS.
The present study was designed to elucidate the
importance of pulsatility of pulmonary arterial flow and
identify its relation to pulmonary vascular dysfunction
after BCPS. The purpose of this study was to evaluate
whether differences in pulsatile flow would be associat-
ed with alterations in endothelial nitric oxide (NO) pro-
duction. In this study we assessed the impact of pul-
satile flow on pulmonary endothelial function using
acetylcholine (ACH), an endothelium-dependent
vasodilator, and compared the effect of ACH with that
T he bidirectional cavopulmonary shunt (BCPS), orbidirectional Glenn shunt, has frequently been per-
formed as a primary palliation or intermediate step
before the ultimate Fontan-type repair in patients with
univentricular heart syndrome.1-4 However, several dis-
advantages regarding nonpulsatile or decreased pul-
satile pulmonary flow after the BCPS have been report-
ed, as well as the importance of flow pulsatility in both
global and microvascular pulmonary circulation.
Objective: Although in vitro studies have suggested the importance of flow
pulsatility in endothelial function, few reports have focused on pulmonary
endothelial function under decreased pulsatile flow after a bidirectional
cavopulmonary shunt with or without an additional pulmonary flow source.
The purpose of the present study was to assess the pulmonary endothelial
function after bidirectional cavopulmonary shunt.
Methods and results: Pulmonary vasodilating response was evaluated in 10
patients 0.4 to 7.0 years (median 1.6 years) after bidirectional cavopul-
monary shunt who were provided an additional flow source by retaining the
pulmonary outflow tract and in 8 control subjects. Average pulmonary flow
velocity was measured with a Doppler flow wire placed in the segmental
lower lobe pulmonary artery during incremental infusion of acetylcholine
(10–8, 10–7, 10–6, and 10–5 mol/L) and then of nitroglycerin (0.5 and 1.0 µg ·
kg–1 · min–1) after recovery. In the control subjects, a dose-dependent
increase in flow velocity was observed in response to acetylcholine (maxi-
mum increase was 155% ± 17% of baseline) and to nitroglycerin (maximum
increase was 151% ± 20% of baseline). In contrast, patients showed a sig-
nificantly impaired response to acetylcholine (maximum increase was 124%
± 17% of baseline; P < .01 vs control), whereas the response to nitroglycerin
was preserved (138% ± 12% of baseline; P = .09 vs control). In addition, the
maximum response to acetylcholine correlated significantly with the pul-
monary pulse pressure (r = 0.89, P < .01) and with the pulmonary flow pul-
satility (r = 0.88, P < .01).
Conclusions: These results clearly suggest that patients after bidirectional
cavopulmonary shunt show pulmonary endothelial functional attenuation
and, of more importance, that decreased pulsatility of cavopulmonary flow
is mainly responsible for this endothelial abnormality. (J Thorac Cardiovasc
Surg 2001;121:1161-8)
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of nitroglycerin (NTG), an endothelium-nondependent
vasodilator and exogenous NO donor.
Methods
Study population. Between January 1996 and September
1997, we studied pulmonary arterial hemodynamics after
BCPS in 10 patients (7 boys and 3 girls) 3 to 17 years old
(median 5.3 years) who were provided additional flow
through patent pulmonary ventricular outflow. All 10 of these
patients underwent cardiac catheterization to determine sur-
gical indications for Fontan completion and post-BCPS
hemodynamic evaluation. The cardiac diagnoses previously
confirmed by cross-sectional echocardiogram, cinean-
giogram, and/or surgical findings are outlined in Table I. The
interval between the BCPS procedure and catheterization
ranged from 0.4 to 7.0 years (median 1.6 years). With respect
to previous operations, all patients had undergone Blalock-
Taussig shunt elimination at BCPS creation. No abnormal
pulmonary venous physiologic condition was demonstrated
by echocardiography and catheterization. Four patients were
being treated preventively with low doses of furosemide,
digoxin, and/or spironolactone, although they had no clinical
sign of congestive heart failure.
We selected 8 patients with normal pulmonary hemody-
namics as control subjects (6 ± 4 years). The group consisted
of 4 patients with mild simple coarctation of the aorta, 1 with
mild aortic stenosis, 1 with mild tricuspid regurgitation, and
2 patients who had undergone repair of coarctation of the
aorta without any residua. 
No participant had parenchymal lung disease or any chro-
mosomal or extracardiac abnormality. Written informed con-
sent was obtained from all participants or their parents.
Study protocol. All medications were discontinued at least
12 hours before the study. All subjects underwent diagnostic
catheterization first under mild sedation (pethidine hydrochlo-
ride) with local anesthesia via the internal jugular and femoral
approach. After the pressure and oxygen measurements,
diazepam (0.2-0.3 mg/kg) was administered intravenously be-
fore the study began. The studies were performed before
angiography. According to body size, a 5F or 6F wedge
catheter was inserted into the medial or posterior branch of the
lower lobe pulmonary artery through the internal jugular vein.
A Doppler flow wire (Cardiometrics, Mountain View, Calif), a
175-cm long, 0.014-inch diameter steerable guidewire with a
12-MHz transducer at its distal tip, was positioned through the
end-hole catheter into a straight segment of the lower lobe pul-
monary artery. Doppler velocity signals were processed with
on-line fast Fourier transform by a real-time spectrum analyz-
er. The Doppler signal was displayed as a continuous spectral
velocity envelope and was recorded onto VHS tape.
After the stability of the Doppler wire and flow signals had
been confirmed, control glucose and vasoactive agents were
infused serially at a maintained rate of 100 mL/min via the
wedge catheter into the segmental pulmonary artery. Doppler
flow signals were obtained during a 3-minute control infu-
sion (5% glucose) and every 3 minutes during incremental
infusion of ACH 10–8, 10–7, and 10–6 mol/L in the presence of
5% glucose. In 4 of the patients who had BCPS, Doppler flow
measurements were taken during an additional infusion of
ACH, 10–5 mol/L, inducing the maximum response to ACH.
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Table I. Cardiac diagnosis in the study population
Case (sex, age [y]) Diagnosis Previous surgery Medication
Patients with BCPS
1 (F, 4.2) DIRV, PS, TAPVC, D-TGA BT shunt D, F, S
2 (M, 3.9) DIRV, PS, TAPVC, D-TGA BT shunt D, F, S
3 (M, 17.0) DIRV, PS, TAPVC, D-TGA BT shunt D, F, S 
4 (M, 5.3) DIRV, PS, TAPVC, D-TGA BT shunt D, F, S
5 (M, 5.5) DIRV, PS, TAPVC, D-TGA BT shunt None
6 (F, 5.3) DIRV, PS, TAPVC, D-TGA BT shunt None
7 (F, 12.0) MA, PS, D-TGA BT shunt None
8 (M, 5.5) PA/IVS BT shunt, RVOTR None
9 (M, 3.0) TA, PS, D-TGA BT shunt None
10 (M, 5.0) corrected TGA, hypoplastic LV BT shunt None
Control subjects
1 (M, 3.0) CoA None None
2 (M, 3.0) CoA None None
3 (M, 11.2) CoA None None
4 (M, 8.0) CoA None None
5 (M, 3.1) CoA Repair None
6 (M, 3.1) CoA Repair None
7 (F, 3.2) AS None None
8 (M, 10.6) Ebstein None None
DIRV, Double-inlet right ventricle; PS, pulmonary stenosis; TAPVC, total anomalous pulmonary venous connection; D-TGA, dextro-transposition of great arteries;
PA/IVS, pulmonary atresia with intact ventricular septum; MA, mitral atresia; TA, tricuspid atresia; CoA, coarctation of the aorta; AS, aortic stenosis; BT, Blalock-
Taussig; RVOTR, right ventricular outflow tract reconstruction; D, digoxin; F, furosemide; S, spironolactone.
After a 4-minute recovery of control infusion, Doppler mea-
surements were repeated during NTG infusions with doses of
0.5 and 1.0 µg · kg–1 · min–1 for 3 minutes each. The mean
flow velocity (in centimeters per second) was calculated and
averaged for the last 30 seconds of each infusion period.
Pulmonary artery branch angiography was then performed
through the catheter to measure the vessel diameter. The mea-
surements were calibrated to the known external diameter of
the non–contrast-filled guiding catheter.
Pulsatility of the pulmonary artery flow was assessed by
the pulmonary pulse pressure and pulsatility index (PI). The
pulmonary pulse pressure was defined as the pressure differ-
ence, which was calculated as systolic peak pressure sub-
tracted from the diastolic pressure nadir, and the PI was cal-
culated as peak systolic flow velocity divided by the diastolic
velocity nadir (Fig 1). Both indicators of the pulmonary flow
pulsatility were averaged for the 30 seconds before the end of
the control glucose infusion.
Statistics. Data are expressed as mean ± SD. Results of the
mean flow velocity for each infusion are expressed as the per-
centage relative to the control value obtained during control
glucose infusion for each subject. Therefore, the paired t test
was used to assess the changes observed in flow velocity.
Comparisons between the 2 groups, the BCPS and control
groups, were performed by means of the unpaired t test.
Linear regression analysis was used to correlate PI and the
percent increase of the mean flow velocity.
Results
Basal hemodynamic profiles of each subject are
shown in Table II. There were no significant differ-
ences in these hemodynamic parameters between the 2
groups except in pulmonary pulse pressure and in sys-
temic arterial oxygen saturation. The pulmonary pulse
pressure in the BCPS group (mean 4 mm Hg) was sig-
nificantly lower than that in the control group (mean 18
mm Hg; P < .01), even with the additional flow.
Pulmonary pulse pressure in patients who had BCPS
varied widely from 1 mm Hg to 10 mm Hg. Systemic
oxygen saturation in the BCPS group was also signifi-
cantly lower than that in the control group (P < .01).
There were no significant changes in systemic pressure
and heart rate monitoring during the infusion of ACH
or NTG, despite a 5% increase in heart rate and an 8%
decrease in systemic pressure during NTG infusion,
and pulmonary pressure little changed. The vessel
diameter at the Doppler flow measurement was 3.5 ±
0.4 mm in the BCPS group and 3.2 ± 0.2 mm in the
control group, showing no significant difference.
Basal pulmonary flow pattern. The characteristic
biphasic pulmonary flow pattern with continuous for-
ward flow was observed in all patients after BCPS.
The flow was increased on electrocardiograms during
both ventricular and atrial systole. During inspiration,
a considerable augmentation of forward flow was
noted. Control subjects, however, had a biphasic pul-
satile pulmonary flow pattern with less basic continu-
ous flow, which was only slightly augmented during
inspiration (Fig 1).
The response of flow velocity to ACH and NTG. In
response to both ACH and NTG, a dose-dependent
increase in mean flow velocity was demonstrated in
both the BCPS and control groups. However, the per-
cent response to ACH was lower in the BCPS group
than in the control group, and the maximum percent
response in the BCPS group was significantly lower
than in the control group (124% ± 17% vs 155% ±
17%; P < .01). The maximum percent increase in
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Fig 1. Spectral Doppler flow velocity in the pulmonary artery. In BCPS, less pulsatile flow with inspiratory aug-
mentation is demonstrated. The pulsatility is calculated as peak systolic flow velocity (S) divided by diastolic nadir
velocity (D) and averaged over 30 seconds before the end of the glucose infusion.
response to NTG, however, did not differ significantly
between the BCPS group and the control group (138%
± 12% vs 151% ± 20%) (Fig 2).
In the BCPS group, the response to ACH was signif-
icantly lower than that to NTG (P < .05), although there
was no significant difference in control group.
The relation between the pulmonary flow pulsatil-
ity and flow velocity in response to ACH in the
BCPS group. The PI in the BCPS group ranged from
1.1 to 10.5 (median 2.5) and the mean value was 3.7 ±
3.2, which was significantly lower than that in the con-
trol group (12.0 ± 5.1; P < .01). In the BCPS group, the
PI was positively correlated with the percent flow
velocity response to ACH (r = 0.89, P < .01). The pul-
monary pulse pressure was also positively correlated
with the maximum increase in response to ACH (r =
0.88, P < .01) (Fig 3). In the response to NTG, there
was no correlation with either PI or pulse pressure.
The maximal ACH percent response to the maximal
NTG percent response ratio (ACH/NTG response
ratio) within each patient was compared between the
BCPS and control groups. The ACH/NTG response
ratio was significantly lower in the BCPS group (0.89
± 0.09) than in control group (1.06 ± 0.12). The
ACH/NTG response ratio was positively correlated
with the PI (r = 0.87; P < .01) (Fig 4).
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Table II. Basal hemodynamic profile in each study group
BCPS group Control group P value
Mean PAP (mm Hg) 14 ± 5 17 ± 3 NS
Pulmonary pulse pressure (mm Hg) 4 ± 3 18 ± 4 <.01
Pulmonary artery oxygen saturation (%) 69 ± 13 72 ± 4 NS
Mean SAP (mm Hg) 83 ± 9 94 ± 17 NS
Systemic artery oxygen saturation (%) 84 ± 8 94 ± 1 <.01
Vessel diameter (mm) 3.5 ± 0.4 3.2 ± 0.2 NS
PAP, Pulmonary artery pressure; SAP, systemic artery pressure; NS, not significant.
Fig 2. Changes in the mean flow velocity in the pulmonary artery. Left, Response to ACH; right, response to NTG;
n.s., not significant. A dose-dependent increase in flow velocity occurred in response to both ACH and NTG infu-
sion (*P < .01, **P < .05). In response to ACH, maximal increase in the flow velocity is significantly lower in
patients with BCPS than in control subjects (#P < .01). In response to NTG, there is no significant difference
between the 2 groups.
Discussion
Numerous experimental studies7-10 have demonstrat-
ed that the endothelium-dependent ACH response is
mainly mediated by NO, because it can be abolished by
Ng-monomethyl-L-arginine or methylene blue. Also,
studies of the human pulmonary artery suggest that an
ACH-mediated response is endothelium-dependent NO
production.11-14 We assessed pulmonary endothelial
function using ACH, an endothelium-dependent vaso-
dilator, and compared the effect of ACH with that of
NTG, an endothelium-nondependent vasodilator and
exogenous NO donor. Many reports have also shown
that the mode of flow plays a major role in modulating
pulmonary hemodynamics, particularly vascular resis-
tance, and lung properties such as water content and
interstitial hydrostatic pressure.5,6,15 It is, therefore, not
so surprising that flow pulsatility relates to hemody-
namic regulation at the level of endothelial cellular
function.
We demonstrated ACH-induced vasorelaxation
(endothelium-dependent vasorelaxation) of the conduit
pulmonary artery to be significantly attenuated in
patients after BCPS, whereas the response to NTG
(endothelium-nondependent vasorelaxation) was well
preserved. These results suggest endothelial dysfunction
and maintained relaxation response of the pulmonary
artery smooth muscle in patients undergoing BCPS. Of
more importance, the degree of impairment in ACH-
mediated response was positively correlated with pul-
monary arterial pulsatility, which depended on the mag-
nitude of supplemental flow in addition to the
cavopulmonary flow. The low pulsatility of pulmonary
flow may be responsible for abnormal hemodynamic
regulation at the endothelial cell level. Our results have
clearly supported that patients after BCPS have attenua-
tion of pulmonary endothelial function, for which low
pulsatility of cavopulmonary flow is mainly responsible.
Pulmonary vascular response in control subjects.
In control children with normal pulmonary hemody-
namics, both ACH and NTG stepped up the mean flow
velocity to a maximum of more than 150% of the base-
line value for the incremental doses given. This means
that the pulmonary vasculature has the potential ability
to accept an increase in pulmonary flow. This is, in
other words, pulmonary vascular reserve against high
pulmonary flow volume. Several reports have demon-
strated endothelium producing NO to be important in
regulating basal pulmonary artery resistance in healthy
human beings,11-13 as well as in patients with pul-
monary vascular disease.16 The maximum ACH-
induced increase, therefore, is a quantitative index of
pulmonary endothelial function or, more specifically,
responsible endothelial NO production.
It remains unclear, however, how much flow velocity
increases in response to ACH or to NTG in the normal
pulmonary artery. We speculate that the maximum pul-
monary vascular reserve in healthy human beings may
be more than 200% of increase. Pulmonary hyperten-
sion rarely occurs clinically in patients with atrial sep-
tal defect, whose pulmonary/systemic flow ratio is
more than 2.0, and in patients undergoing unilateral
lobectomy. We studied mainly the NO-dependent
vasodilative property in this study; other vasodilative
substances such as prostacyclin or endothelium-derived
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Fig 3. In patients with BCPS, correlation between the flow velocity response to ACH and the PI (left) and the pul-
monary pulse pressure (right).
hyperpolarizing factor may contribute further to the
vasodilative response.
Pulmonary vascular response in patients after
BCPS. The precise mechanism causing the attenua-
tion of ACH-mediated endothelial response in patients
after BCPS must be further explored. Recent in vitro
studies have demonstrated that the different flow pat-
terns result in alterations of fluid shear stress and sub-
sequently modulate expression of genes encoding
basic fibroblast growth factor, platelet-derived growth
factor,17 tissue factor,18 and synthesis of NO19 in the
endothelium. The low pulsatile flow after BCPS
resulting in low shear stress may contribute to the
attenuation of endothelial NO production. Previous
studies20 have shown pulsatile flow to be a more pow-
erful stimulus to the release of NO than steady flow,
implying that endothelial cells are sensitive to the
magnitude of shear stress.
The pulsatility of blood flow may significantly influ-
ence both endothelial morphologic characteristics and
function through the molecular responses to shear
stress.21 A recent experimental study22 elucidated that
the microfilament actin of one of the essential
cytoskeletal proteins was redistributed in endothelial
cells by shear-induced stimuli. Another study23 showed
that the 5´ flanking region of endothelial NO synthase
contains a cis-acting regulatory sequence identical to
the shear-stress responsive element, indicating that
shear-stress directly upregulates endothelial NO syn-
thase gene transcription. To the contrary, lessened pul-
satile flow pattern, that is, reduced shear stress, may
downregulate endothelial NO synthase expression and
may attenuate the endothelium-dependent vasodilative
response in patients after BCPS.
Systemic arterial oxygen saturation, which may
affect the endothelial response,15 was significantly
lower in patients than in control subjects. These
patients have had hypoxia since birth, and oxygen con-
centration in their bronchial arteries, which supply
oxygen to both the pulmonary endothelium and the
smooth muscle cells, is lower than that of control sub-
jects. Although we did not observe any connection to
arterial oxygen saturation in this study, the hypoxic
endothelium may be associated with the attenuation. In
addition, the response to NTG tended to be lower,
although the difference in response between patients
after BCPS and control subjects was not significant.
Low oxygen content in the bronchial artery may also
mediate attenuation of the effector mechanism in vas-
cular endothelial and smooth muscle cells and, conse-
quently, limit vasorelaxant response.
The vascular endothelium is not only a semiperme-
able barrier between the blood and interstitium but
also a homeostatic organ with physiologic, biologic,
and endocrinologic functions. Not only is NO synthe-
sized in the endothelium as a potent vasodilator24 but
it also reduces platelet aggregation and adhesion,25
monocyte-vessel wall interaction, and smooth muscle
proliferation,26 all of which may impair the ability of
the pulmonary vascular endothelium to regulate micro-
circulation in patients after BCPS.
Study limitations. This study demonstrated the
percent increase of mean velocity response to ACH
and NTG but did not calculate the percent increase of
flow volume, because vascular diameter was not mea-
sured at the end of each drug infusion. Frequent
angiography was not performed, because we assumed
that frequent contrast infusions would have a deleteri-
ous influence on vascular endothelial function,
change the vascular reflex, or modify the endotheli-
um-dependent vasorelaxant response. A previous
angiographic study has shown that pulmonary artery
diameter changed little during ACH infusion (1% ±
1%), that it increased modestly in response to NTG
infusion (5% ± 1%) in control subjects, and that it
changed little during both ACH and NTG infusion in
patients with secondary pulmonary hypertension.
These observations indicate that the major site of
action of each agent is distal to the segmental pul-
monary arteries, that is, the downstream resistance
vessels.16 Our Doppler flow wire method has been
validated previously ex vivo and demonstrates excel-
lent linear correlation to volumetric flow with R2 val-
ues between 0.98 and 1.00.27,28 We, therefore, consid-
ered average flow velocity analysis to allow accurate
assessment of changes in flow volume in this study.
1166 Kurotobi et al The Journal of Thoracic and
Cardiovascular Surgery
June 2001
Fig 4.  In all subjects, correlation between the maximal ACH
percent response to the maximal NTG percent response ratio
and the PI. Open circle, Control group; Closed square, BCPS
group.
In the clinical setting, unlike in vitro study, it is diffi-
cult to keep blood concentrations of both ACH and
NTG consistent between BCPS and control subjects at
the Doppler flow sampling site, because each partici-
pant has a different cardiac output and pulmonary flow
volume. In addition, it is difficult to calculate the pul-
monary flow volume in patients with BCPS having the
additional flow. However, there was no difference in
the vessel diameter on measurements between the 2
groups, and consistent results were obtained under the
wide range of ACH concentrations.
The patient group is heterogeneous by diagnosis,
surgery, and medication. Thus, interference of the dif-
ferent underlying and pre-existing cardiac anatomic
abnormalities, of the surgical approach, or of long-term
medication may have some influence on endothelial
responsiveness. Further, the group that was used as a
control group was not completely normal because of
pre-existing cardiovascular abnormalities. However,
such patients with complex cardiac abnormalities are
restricted in number and homogeneity. In addition, we
cannot ethically study children without cardiovascular
disease.
Finally, we did not study patients without additional
pulmonary flow. However, the patients without addi-
tional flow should have less pulsatility than our
patients. Indeed, in this study, 1 patient with severe pul-
monary stenosis, almost pulmonary atresia, had the
lowest PI of all.
Clinical implications. The BCPS has become an
important staging procedure for the Fontan-type opera-
tion in the management of patients with univentricular
heart syndrome. Accessory pulmonary blood in BCPS
is still controversial. Proponents suggest that a dual
source of pulmonary blood flow results in more satis-
factory levels of arterial saturation, but opponents
emphasize the merits of eliminating volume load to the
heart. Our observations suggest that pulmonary flow
pulsatility has crucial effects and support the utility of
BCPS with additional pulmonary flow from the stand-
point of pulmonary endothelial function.
Our data show good flow velocity response to ACH
in 2 patients after BCPS with pulmonary pulse pressure
of more than 8 mm Hg and PI of more than 8. This
favorable response suggests that pulse pressure of more
than 8 mm Hg for pulsatility is preferable to prevent
pulmonary endothelial functional attenuation under
BCPS if the ventricular function is stable.
Conclusions
Endothelium-dependent pulmonary artery relaxation
response to ACH was attenuated in patients after
BCPS, and the degree of attenuation was negatively
correlated with the pulmonary flow pulsatility.
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